
- Pharmaceutical Technology, September 2024
- Volume 48
- Issue 9
- Pages: 8
Responding to Mpox
A coordinated and international response is needed to help control the latest mpox outbreak in Africa.
On Aug. 14, 2024, the World Health Organization (WHO) declared mpox (previously called monkeypox) as a public health emergency of international concern (PHEIC) as a result of the increasing rates of infection that are being witnessed in African countries (1). The International Health Regulations Emergency Committee of independent experts had advised WHO on the level of concern about the spread of the virus and the potential for the virus to penetrate other continents.
Two years ago, in July 2022, the multi-country outbreak of mpox was also declared a PHEIC; however, after less than a year, in May 2023, that PHEIC was declared over as a sustained decline in global cases was seen (1). A new virus strain of mpox, clade 1b, has emerged and has been rapidly spreading.
When the first PHEIC was declared for mpox in 2022 for a less deadly strain of the virus, the bio/pharma industry went to bat quickly and utilized experience from the COVID-19 pandemic to work efficiently. One of the main players from the 2022 outbreak, Bavarian Nordic, is proving its worth once again, committing to donate 40,000 doses of its mpox vaccine to the Africa Centers for Disease Control and Prevention (2). “Mpox is spreading at an alarming rate in Africa, calling for further action from the international community,” said Paul Chaplin, president and chief executive officer of Bavarian Nordic, in a press release (2).
The 40,000 vaccines from Bavarian Nordic will form part of a larger donation of 215,000 doses that will be provided by the European Commission’s Health Emergency Preparedness and Response Authority (3). However, many more vaccines will be needed, and WHO has triggered the Emergency-Use Listing process for mpox vaccines and started working with countries and vaccine manufacturers on potential donations (1).
“The emergence of a new clade of mpox, its rapid spread in eastern DRC [Democratic Republic of Congo], and the reporting of cases in several neighbouring countries are very worrying,” warned Dr Tedros Adhanom Ghebreyesus, director-general of WHO, in his PHEIC declaration announcement (1). “On top of outbreaks of other mpox clades in DRC and other countries in Africa, it’s clear that a coordinated international response is needed to stop these outbreaks and save lives.”
References
1. WHO. WHO Director-General Declares Mpox Outbreak a Public Health Emergency of International Concern. Press Release, Aug. 14, 2024.
2. Bavarian Nordic. Bavarian Nordic Receives Order from HERA and Announces Significant Donation of Vaccines in Response to the Mpox Outbreak in Africa. Press Release, Aug. 13, 2024.
3. EC. Mpox: HERA to Donate Over 215,000 Vaccines to Africa CDC Amid Urgent Outbreak. Press Release, Aug. 14, 2024.
About the author
Mike Hennessy Jr is president and CEO of MJH Life Sciences®
Article details
Pharmaceutical Technology®
Vol. 48, No. 9
September 2024
Page: 8
Citation
When referring to this article, please cite it as Hennessy, M. Responding to Mpox. Pharmaceutical Technology 2024 48 (9) 8.
Articles in this issue
about 1 year ago
Understanding the Value of Excipient Gradeabout 1 year ago
Determining Low PPB Levels of Nitrite in Polymeric Excipientsabout 1 year ago
Molecular Modeling in Formulation Developmentabout 1 year ago
Advancing Robotic Automationabout 1 year ago
Meeting Adventitious Agent Testing Needs for Complex Modalitiesabout 1 year ago
It’s All About the Small Thingsabout 1 year ago
Strategic Decarbonizationabout 1 year ago
Keeping Audit and Inspection Programs Currentabout 1 year ago
European Artificial Intelligence Act Comes into Forceabout 1 year ago
Separation and Purification Columns for Enhanced RetentionNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.





